# Afatinib in Advanced Refractory Urothelial Cancer

> **NCT02122172** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 32 (actual)

## Conditions studied

- Distal Urethral Cancer
- Proximal Urethral Cancer
- Recurrent Bladder Cancer
- Recurrent Urethral Cancer
- Stage III Bladder Cancer
- Stage III Urethral Cancer
- Stage IV Bladder Cancer
- Stage IV Urethral Cancer
- Ureter Cancer

## Interventions

- **DRUG:** afatinib dimaleate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02122172
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-13
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-04-04
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Unable to meet accrual goal after several years
- **Last updated:** 2025-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02122172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02122172, "Afatinib in Advanced Refractory Urothelial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02122172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*